Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis

European Journal of Neurology

Volumn 20, Issue 6, 2013, Pages 907-e79

  Baumstarck, K ^a   Pelletier, J ^b   Butzkueven, H ^c,d   Fernandez O ^e   Flachenecker, P ^f   Idiman, E ^g   Stecchi, S ^h   Boucekine, M ^a   Auquier, P ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^f Neurological Rehabilitation Center Quellenhof   (Germany)

^g DOKUZ EYLUL UNIVERSITY   (Turkey)

^h IRCCS Instituto Delle Scienze Neurologiche di Bologna   (Italy)

Author keywords

Disability; Expanded Disability Status Scale; Longitudinal study; multiple sclerosis; MusiQoL; Predictors; Quality of life; SF 36

Indexed keywords

ACTIVITIES OF LIVING MODEL; ADULT; AGE; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISABILITY; DISEASE DURATION; DISEASE SEVERITY; EDUCATIONAL STATUS; EMPLOYMENT STATUS; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GENDER; HEALTH BEHAVIOR; HEALTH CARE PERSONNEL; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEASUREMENT ACCURACY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; SHORT FORM 36;

EID: 84877654538     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12087     Document Type: Article

References (37)

1. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998; 352: 1491-1497.
2. Ellison GW, Myers LW, Leake BD, et al. Design strategies in multiple sclerosis clinical trials. The Cyclosporine Multiple Sclerosis Study Group. Ann Neurol 1994; 36(Suppl): S108-S112.
3. Bergamaschi R, Berzuini C, Romani A, Cosi V. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci 2001; 189: 13-21.
4. Debouverie M, Pittion-Vouyovitch S, Brissart H, Guillemin F. Physical dimension of fatigue correlated with disability change over time in patients with multiple sclerosis. J Neurol 2008; 255: 633-636.
5. Rudick RA, Lee JC, Cutter GR, et al. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. Arch Neurol 2010; 67: 1329-1335.
6. Myhr KM, Riise T, Vedeler C, et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler 2001; 7: 59-65.
7. Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 2003; 9: 260-274.
8. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 2006; 63: 1686-1691.
9. Achiron A, Barak Y, Rotstein Z. Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis. Mult Scler 2003; 9: 486-491.
10. Bosma LV, Kragt JJ, Knol DL, Polman CH, Uitdehaag BM. Clinical scales in progressive MS: predicting long-term disability. Mult Scler 2012; 18: 345-350.
11. Gholipour T, Healy B, Baruch NF, Weiner HL, Chitnis T. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology 2011; 76: 1996-2001.
12. Li DK, Held U, Petkau J, et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 2006; 66: 1384-1389.
13. Schlaeger R, D'Souza M, Schindler C, et al. Prediction of long-term disability in multiple sclerosis. Mult Scler 2012; 18: 31-38.
14. Villar LM, Masjuan J, Gonzalez-Porque P, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002; 59: 555-559.
15. Yeo W, Mo FK, Koh J, et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol 2006; 17: 1083-1089.
16. Meyer F, Fortin A, Gelinas M, et al. Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy. J Clin Oncol 2009; 27: 2970-2976.
17. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life as a predictor for change in disability in MS. Neurology 2000; 55: 51-54.
18. Visschedijk MA, Uitdehaag BM, Klein M, et al. Value of health-related quality of life to predict disability course in multiple sclerosis. Neurology 2004; 63: 2046-2050.
19. Guarnaccia JB, Aslan M, O'Connor TZ, et al. Quality of life for veterans with multiple sclerosis on disease-modifying agents: relationship to disability. J Rehabil Res Dev 2006; 43: 35-44.
20. Benito-Leon J, Mitchell AJ, Rivera-Navarro J, Morales-Gonzalez JM. Impaired health-related quality of life predicts progression of disability in multiple sclerosis. Eur J Neurol 2012; 20: 79-86.
21. Polman CH, Wolinsky JS, Reingold SC. Multiple sclerosis diagnostic criteria: three years later. Mult Scler 2005; 11: 5-12.
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
23. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308: 173-180.
24. Simeoni M, Auquier P, Fernandez O, et al. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult Scler 2008; 14: 219-230.
25. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
26. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
27. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63: 1779-1787.
28. Goodkin DE. EDSS reliability. Neurology 1991; 41: 332.
29. Bergamaschi R, Quaglini S, Trojano M, et al. Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. J Neurol Neurosurg Psychiatry 2007; 78: 757-759.
30. Amato MP, Ponziani G, Bartolozzi ML, Siracusa G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999; 168: 96-106.
31. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27: S217-S232.
32. Trojano M, Avolio C, Manzari C, et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995; 58: 300-306.
33. Scott TF, Schramke CJ. Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later. J Neurol Sci 2010; 292: 52-56.
34. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006; 5: 343-354.
35. Ebers GC. Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol 2005; 252(Suppl 3): iii15-iii20.
36. Kantarci O, Siva A, Eraksoy M, et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 1998; 51: 765-772.
37. Arnett PA, Randolph JJ. Longitudinal course of depression symptoms in multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 606-610.